Stay updated on Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page
- Check7 days agoChange DetectedThe Locations section was updated to replace Kharkivs’ka Oblast’ with Kharkiv Oblast and to add a new entry for Kharkiv, Kharkiv Oblast, Ukraine, 61070; the former Kharkivs’ka Oblast’ entry (and its city/ZIP) was removed.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedRevision tag on the study page updated from v3.5.3 to v3.5.4. This reflects a new internal update to the page’s revision history.SummaryDifference0.0%

- Check28 days agoNo Change Detected
- Check42 days agoChange DetectedThe ClinicalTrials.gov page’s revision label was updated from version v3.5.0 to v3.5.3.SummaryDifference0.0%

- Check78 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3 on the page.SummaryDifference0.0%

- Check93 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check107 days agoChange DetectedPlain Language Summary added to the Study Details page. The update also lists recent change dates (2026-02-17, 2026-02, 2026-02-19) alongside the new content.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.